Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Cancer Prev Res (Phila). 2010 May 18;3(6):718–726. doi: 10.1158/1940-6207.CAPR-10-0048

Fig. 2.

Fig. 2

Immunoblotting for cIAP1, XIAP, and survivin using lysates from MCF-7 and MDA-MB-231 cells treated with DMSO (control) or BITC (2.5 or 5.0 µmol/L) for the indicated time periods. Numbers above bands represent densitometric quantitation relative to corresponding DMSO-treated control. Immunoblotting for each protein was performed at least twice using independently prepared lysates. Representative data from one such experiment are shown.